<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959113</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD 131244.1</org_study_id>
    <nct_id>NCT01959113</nct_id>
  </id_info>
  <brief_title>Validation of the Short-term Antimicrobial Action of Transplanted Bacteria</brief_title>
  <official_title>Phase 1 Study of the Short-term Antimicrobial Action of Transplanted Bacteria in Adult Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently
      colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of
      S. aureus skin infections. In addition, research in the investigator's lab has shown that
      these patients have fewer protective antimicrobial Staphylococcal species such as
      Staphylococcal epidermidis (S. epidermidis) that are known to produce antimicrobial peptides
      that play a role in protecting the skin from invading pathogens. In this study, the
      investigator will attempt to decrease S. aureus colonization and increase colonization by
      protective Staph species in AD patients. First the investigator will capture the bacteria on
      subjects' lesional AD skin. Next the investigator will selectively grow the subject's
      antimicrobial Staphylococcal colonies and place them into a base moisturizer. The moisturizer
      plus bacteria will be applied to one of the subject's arms, and the moisturizer alone
      (without bacteria) to the other arm. The investigator will then do a quantitative wash of the
      bacteria growing on each arm one day later in order to determine whether the S. aureus
      abundance was affected by the application of the transplanted bacteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Staphylococcus Aureus Abundance</measure>
    <time_frame>24-hours post-transplant</time_frame>
    <description>The technique of quantitative washes will be used to determine the Staphylococcus aureus abundance on an area of lesional AD skin on the subject's forearm as a ratio of baseline S. aureus abundance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Autologous Microbiome Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will have a base moisturizer alone applied to it during the third visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Microbiome Transplant</intervention_name>
    <arm_group_label>Autologous Microbiome Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Arm</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>The placebo arm will have a commercially available moisturizer applied to it.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects who are not pregnant or lactating

          -  18-80 years of age

          -  Diagnosis of atopic dermatitis for at least 6 months using the Hanifin and Rajka
             Diagnostic Criteria for atopic dermatitis

          -  Presence of lesional atopic dermatitis skin in both antecubital fossae

          -  Positive methicillin-sensitive S. aureus colonization based on results of a skin
             culture taken from one of their AD-affected antecubital fossae during the screening
             visit

        Exclusion Criteria:

          -  Use of any topical AD treatments (including topical steroids, topical calcineurin
             inhibitors) to either arm within one week of either screening visit

          -  Use of any oral/systemic AD therapies (antihistamines, steroids) within 28 days of
             either screening visit

          -  Severe AD that would worsen significantly from holding a participant's usual
             topical/oral AD medications for the time periods required in the inclusion/exclusion
             criteria (one week prior to the screening visits and during the study for topical
             medications and 28 days prior to screening visits and during the study for oral
             medications)

          -  Subjects who have taken a bleach bath within a week prior to screening, or who take
             bleach baths during the study

          -  Patients with severe medical condition(s) that in the view of the investigator
             prohibits participation in the study

          -  Subjects with Netherton's syndrome or other genodermatoses that result in a defective
             epidermal barrier

          -  Any subject who is immunocompromised (e.g. provides researchers with a history
             lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome) or has a history of malignant disease
             (with the exception of non-melanomatous skin cancer). This information will be
             gathered verbally from the patient while taking a medical history from the patient,
             and will not involve further testing such as an HIV test.

          -  Subjects with a history of psychiatric disease or history of alcohol or drug abuse
             that would interfere with the ability to comply with the study protocol

          -  Active bacterial, viral or fungal skin infections

          -  Any noticeable breaks or cracks in the skin on either arm, including severely
             excoriated skin or skin with open or weeping wounds suggestive of an active infection
             or increased susceptibility to infection.

          -  Ongoing participation in another investigational trial

          -  Use of any oral or topical antibiotic for up to four weeks prior to screening

          -  Use of any systemic immunosuppressive therapy (e.g. cyclosporin, methotrexate, etc.)
             within four weeks of screening.

          -  Sensitivity to or difficulty tolerating Dove fragrance-free bar soap, Dial
             antibacterial liquid soap, Cetaphil lotion, or alcohol-based cleaners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Division of Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>June 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2020</results_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Richard Gallo</investigator_full_name>
    <investigator_title>Professor and Chair, Division of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Bacteria transplant</keyword>
  <keyword>Atopic dermatitis treatments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults with AD were recruited from the University of California, San Diego (UCSD), La Jolla, CA, and the National Jewish Health (NJH), Denver, CO.</recruitment_details>
      <pre_assignment_details>All subjects avoided any treatments and therapies that may potentially affect skin microbiome before sample collection.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Autologous Microbiome Transplant and Placebo (Split-design)</title>
          <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
Autologous Microbiome Transplant
Placebo vehicle cream will be applied to the contralateral arm. This arm is the placebo arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>5 subjects with AD were enrolled in the study. Each of the subject's arms was randomly assigned to treatment with AMT or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Autologous Microbiome Transplant and Placebo (Split-design)</title>
          <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
Autologous Microbiome Transplant
Placebo vehicle cream will be applied to the contralateral arm. This arm is the placebo arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Staphylococcus Aureus Abundance</title>
        <description>The technique of quantitative washes will be used to determine the Staphylococcus aureus abundance on an area of lesional AD skin on the subject's forearm as a ratio of baseline S. aureus abundance</description>
        <time_frame>24-hours post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>This arm will have a base moisturizer alone applied to it during the third visit.
Placebo Arm</description>
          </group>
          <group group_id="O2">
            <title>Autologous Microbiome Transplant</title>
            <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
Autologous Microbiome Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Staphylococcus Aureus Abundance</title>
          <description>The technique of quantitative washes will be used to determine the Staphylococcus aureus abundance on an area of lesional AD skin on the subject's forearm as a ratio of baseline S. aureus abundance</description>
          <units>ratio to baseline S. aureus abundance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>arms</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>arms</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.2"/>
                    <measurement group_id="O2" value="12.2" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after baseline visit</time_frame>
      <desc>Participants were asked about adverse events by phone 30 days after baseline visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Autologous Microbiome Transplant</title>
          <description>Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
Autologous Microbiome Transplant</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Split-design)</title>
          <description>Placebo vehicle cream will be applied to the contralateral arm. This arm is the placebo arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials Unit</name_or_title>
      <organization>University of California, San Diego</organization>
      <phone>858-657-8390</phone>
      <email>dermstudies@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

